What is the clinical evidence from this study?

Study design: Cohort. Population: High or very high risk for ASCVD (n=900). Intervention: Statin therapy vs. Baseline (pre-treatment). Primary outcome: Postprandial triglyceride (pTG) concentration.

What does this research mean for the field?

Statin treatment normalizes abnormal postprandial lipemia in approximately 75% of high-risk ASCVD patients and decreases postprandial triglyceride concentrations even in individuals with normal fasting triglyceride levels. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

March 3, 2026Current Vascular Pharmacology

Hellenic Postprandial Lipemia Study (HPLS): A Prospective Cohort Trial on the Effect of Statins on Postprandial Hypertriglyceridemia

View Full Paper

Ask AI

Bookmark

Key result

Statin therapy normalizes abnormal postprandial lipemia in ~76% of high-risk patients.

n=900

Why the study?

Does statin therapy improve postprandial hypertriglyceridemia in individuals at high or very high risk for ASCVD?

Population

Individuals at high-/very high-risk for ASCVD

Comparison

Statin treatment

Design

Prospective cohort trial

Authors

GKGenovefa D. KolovouMetropolitan Hospital TKTheodoros KatsikasSotiria General Hospital PKPetros Kalogeropoulos

Discussion

Member takes

Implication

Supports statins for postprandial hypertriglyceridemia in high-risk ASCVD; extends benefit to normal fasting TG.

Key Points

Normalization of abnormal postprandial lipemia occurs in most high-risk individuals following statin therapy, reducing both fasting and meal-related lipids.
Postprandial hypertriglyceridemia normalized in 75.6% of treated patients, while mean post-meal triglyceride differences decreased by 29 mg/dL at follow-up.
Prospective cohort trial evaluation demonstrates that statin therapy reliably curbs postprandial lipemia, highlighting vital benefits against vascular disease.

Study Design

Type

Cohort (n=900)

Structured PICO

Does statin therapy improve postprandial hypertriglyceridemia in individuals at high or very high risk for ASCVD?

Population

900 individuals at high or very high risk for ASCVD, evaluated for postprandial lipemia before and after 3-4 months of statin therapy.

Intervention

Statin therapy

Comparator

Pre-treatment baseline (Visit 2)

Outcome

Serum triglyceride (TG) levels measured after a 12-hour fast (fTG) and 4 hours after the ingestion of a commercially available oral fat tolerance test meal (pTG) at 3-4 monthssurrogate

Main Result

Absolute Event Rate: 140% vs 188%

Statin therapy effectively normalizes abnormal postprandial lipemia in the majority of high-risk ASCVD patients, including those with normal fasting triglycerides.

Cite This Study

Kolovou et al. (2026) conducted a cohort in High or very high risk for ASCVD (n=900). Statin therapy vs. Baseline (pre-treatment) was evaluated on Postprandial triglyceride (pTG) concentration. Statin therapy normalized abnormal postprandial lipemia in 75.6% of high-risk participants and decreased mean postprandial triglyceride concentrations from 188 mg/dL to 140 mg/dL.

synapsesocial.com/papers/69a75a6fc6e9836116a20403 https://doi.org/10.2174/0115701611390916251104053059

View Full Paper

Ask AI

Bookmark

Hellenic Postprandial Lipemia Study (HPLS): A Prospective Cohort Trial on the Effect of Statins on Postprandial Hypertriglyceridemia

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Main Result

Cite This Study

Hellenic Postprandial Lipemia Study (HPLS): A Prospective Cohort Trial on the Effect of Statins on Postprandial Hypertriglyceridemia

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Main Result

Cite This Study

Also Consider

Also Consider